Develops a Microcycle® platform that enables direct screening of small molecule libraries within mammalian cells, facilitating the discovery of biologically active compounds. This approach targets complex disease mechanisms, such as challenging cancer targets, that are often inaccessible to traditional drug discovery methods.
Funding
$57.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PVFounders
Product
Problem
Traditional drug discovery methods often struggle to identify small molecule therapeutics that effectively target complex intracellular disease mechanisms, particularly in challenging cancer targets. Screening compound libraries outside of the cellular environment can miss crucial interactions and biological context, leading to high failure rates in later stages of drug development.
Solution
Curve Therapeutics offers the Microcycle® platform, an innovative intracellular screening technology that enables direct evaluation of small molecule libraries within mammalian cells. This approach facilitates the discovery of biologically active compounds that modulate complex disease mechanisms inaccessible to conventional methods. By screening directly inside cells, the platform captures relevant biological context and identifies compounds with improved efficacy and target engagement. The platform is currently being used to build a pipeline of first-in-class small molecule drugs focused on high-priority cancer targets that have evaded traditional discovery approaches.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions seeking novel small molecule therapeutics for complex diseases, particularly in oncology.
Features
- Direct screening of small molecule libraries within mammalian cells
- Identification of biologically active compounds targeting complex intracellular mechanisms
- Hit-to-lead programs facilitated by the Microcycle® platform
- Focus on challenging cancer targets that have evaded conventional approaches